Full Text of PDF (406k)
Article in Japanese
Abstract
Case Report
Pembrolizumab-induced bullous pemphigoid in non-small cell lung cancer: a two-case report
Yu Kitamuraa Masachika Fukuia Akihiro Tsukamotoa Yuka Sasakia Komei Yanasea Hiroyuki Okurab
aDepartment of Respiratory Medicine, Tokai National Higher Education and Research System, Gifu University
bDepartment of Cardiology, Tokai National Higher Education and Research System, Gifu University
ABSTRACT
While pruritus and erythema multiforme are known immune-related adverse skin reactions associated with pembrolizumab, cases of bullous pemphigoid have also been reported. Notably, reports suggest that patients who develop bullous pemphigoid may be more likely to experience anti-tumor effects against cancer. Treatment typically involves the use of topical steroids and systemic administration. However, it is important to note that severe cases have been documented, emphasizing the importance of prompt action and collaboration with dermatologists and pathologists. In this report, we present two cases of bullous pemphigoid occurring during pembrolizumab treatment in patients with non-small cell lung cancer.
KEYWORDS
Pembrolizumab Immune-related adverse event (irAE) Bullous pemphigoid (BP) Non-small cell lung cancer
Received 30 Oct 2023 ／ Accepted 13 Feb 2024
AJRS, 13(3): 111-115, 2024
Copyright © The Japanese Respiratory Society All Rights Reserved.